Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Azeliragon by Cantex Pharmaceuticals for Metastatic Pancreatic Cancer: Likelihood of Approval
Azeliragon is under clinical development by Cantex Pharmaceuticals and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...
Azeliragon by Cantex Pharmaceuticals for Refractory Brain Metastasis: Likelihood of Approval
Azeliragon is under clinical development by Cantex Pharmaceuticals and currently in Phase II for Refractory Brain Metastasis. According to GlobalData,...
Azeliragon by Cantex Pharmaceuticals for Cognitive Impairment: Likelihood of Approval
Azeliragon is under clinical development by Cantex Pharmaceuticals and currently in Phase II for Cognitive Impairment. According to GlobalData, Phase...
Azeliragon by Cantex Pharmaceuticals for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Azeliragon is under clinical development by Cantex Pharmaceuticals and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to...
Azeliragon by Cantex Pharmaceuticals for Pneumonia: Likelihood of Approval
Azeliragon is under clinical development by Cantex Pharmaceuticals and currently in Phase III for Pneumonia. According to GlobalData, Phase III...
Azeliragon by Cantex Pharmaceuticals for Refractory Brain Metastasis: Likelihood of Approval
Azeliragon is under clinical development by Cantex Pharmaceuticals and currently in Phase II for Refractory Brain Metastasis. According to GlobalData,...